Podcasts

Our podcast, “Not So Different,” provides insights from and discussions with stakeholders from across the biosimilars landscape.
We sat down with Joe Fuhr, PhD, professor emeritus of economics at Widener University in Chester, Pennsylvania, and an expert on antitrust health economics and pharmacoeconomics to discuss the current state of the biosimilar landscape and what he sees going forward.
In this episode of Not So Different, we sat down with Nick Mitrokostas, an intellectual property (IP) lawyer and partner at Goodwin's IP Litigation group, to discuss how the approval of Pfizer’s pegfilgrastim biosimilar (Nyvepria) will affect the biosimilar market and what he sees for the rest of 2020.
 
We sat down with Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the AAM, to discuss some of the advocacy changes the organization is looking to advance and their chances of approval. 
We sat down with Ha Kung Wong, an intellectual property law attorney and partner at Venable Fitzpatrick in New York and April Breyer Menon, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago, Illinois, to discuss potential bills to improve biosimilar uptake and their chances for passage.
April Breyer Menon, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago, Illinois, discussed 2 pieces of legislation that have the potential to address barriers to biosimilar market entry including the Hatch-Waxman Integrity Act and the Stop Stalling Act.
Noelle Sunstrom, CEO and founder of NeuClone, of Redfern, Australia, discusses the company's future US market prospects and its plans to differentiate from other biosimilar developers.
This week on the podcast, we’re speaking with Sang-Jin Pak, MD, the executive vice president of Samsung Bioepis’ Commercial Division.
This week on the podcast, we’re speaking with Sang-Jin Pak, MD, the executive vice president of Samsung Bioepis’ Commercial Division.
This week on the podcast, we’re speaking with the executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), Cate Lockhart, PharmD, PhD, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how the new approval pathway for biologics will affect the pace at which biosimilars come to market.
With pharmaceutical spending at record levels, employers are looking for solutions and are hopeful that biosimilars can play a role in controlling costs. On this episode, we speak with representatives of EmployersRX, a new coalition made up of 3 employer groups that are advocating for measures that would provide relief for the largest purchasers of healthcare. 

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.